GSK China partners with JD to drive “Internet + Healthcare” to improve patient experience and access to healthcare

Today, GSK China and JD.com, China’s largest retailer, signed an MOU of strategic collaboration. Under the MOU, the two partners will fully leverage each other’s complementary strengths in healthcare, pharmaceuticals and internet applications and work together to create innovative solutions that improve patient experience across the whole healthcare ecosystem and value chain, from seeking treatment to receiving care and to managing health.

Today, GSK China and JD.com, China’s largest retailer, signed an MOU of strategic collaboration. Under the MOU, the two partners will fully leverage each other’s complementary strengths in healthcare, pharmaceuticals and internet applications and work together to create innovative solutions that improve patient experience across the whole healthcare ecosystem and value chain, from seeking treatment to receiving care and to managing health.

The State Council recently issued Opinions on Driving “Internet + Healthcare” Development. The strategic collaboration between GSK China and JD.com is a key step in answering the government’s call for “Internet + Healthcare”, and the partnership will focus on patient needs, target challenging issues including access and affordability of healthcare, and provide patients with one-stop and closed-loop solutions.

For example, big data will be used in analysing user behaviours so as to offer precise and customised disease education; online hospitals will be enlisted to provide patients with health management and disease treatment solutions; cloud-based direct-to-patient (DTP) pharmacy services will be used to meet patients’ medication needs; the IoT will be used for smart drug refills for patients; health insurance can be further explored to ease financial burden and improve patient drug compliance; finally, programmes including targeted health poverty alleviation projects will be rolled out.

5 May was World Pulmonary Hypertension Day. A key component of the strategic collaboration between GSK China and JD.com, “JD Now”, a smart Internet of Things (IoT) healthcare project integrating online hospitals and IoT application, was launched on that day. It offers patients with pulmonary arterial hypertension (PAH) in remote areas with limited mobility a convenient, fast and smart solution, saving them or their families long trips to the doctors or pharmacists to refill their prescriptions, thereby easing burden of disease treatment.

Mr Lijun Xin, President of JD Home and Life, said, “JD is China’s largest retailer. Our partnership with GSK, a world-leading multinational healthcare company, allows us to integrate resources, and combine?GSK’s expertise in professional drug and vaccine development and production with JD’s user resources and technical knowhow. Through our cross-sector collaboration to further enable healthcare, we hope to deliver users a more professional and accessible disease prevention and treatment experience.”?

Mr. Thomas Willemsen, Chairman of GSK (China) Investment Co., Ltd., said, “GSK has always been dedicated to improving public access to innovative solutions in disease prevention and treatment. Internet-based healthcare is a key link in China’s national health strategy. Through our strategic collaboration with JD.com, a pioneer in online healthcare and pharmaceutical services, we are committed to exploring and developing ‘Internet + Healthcare’ solutions against the strategic backdrop of ‘Healthy China 2030’ and ultimately improving Chinese people and patients’ healthcare service quality and accessibility.”

GSK in China with China for China

GSK is committed to supporting the healthcare reform of the Chinese government and to ensuring that Chinese patients can access our innovative treatments targeting their specific needs. As part of our strategy to be "in China, with China, for China", we have achieved the following milestones in recent years:

  • Anoro Ellipta, a new once-daily dual bronchodilators treatment for COPD, was approved in March 2018.
  • Our innovative antiretroviral Single Tablet Regimen (STR) Triumeq was officially launched in January 2018.
  • Supported the launch of “New Respiration and Frequent Care” online management platform for asthma patients in December 2017.
  • Supported the launch of the UK-China Health and Economy Partnership in November 2017.
  • Supported the launch of "Happy Breath" COPD Tiered Diagnosis and Treatment Project across China in November 2017.
  • Flixotide Nebules received approval for the treatment of children asthma in September 2017.
  • Announced partnership with Ali Health to launch innovative online service platform to improve adult vaccination consultation experience in August 2017.
  • Innovative antiretroviral?Single Tablet Regimen (STR) Triumeq received approval in China in August 2017.
  • Cervarix, the first vaccine for cervical cancer prevention in mainland China, was officially launched in July 2017.
  • Announced collaboration programme to aid hepatitis prevention and treatment in poverty-stricken areas of the western region in July 2017.
  • Seroxat CR and Tykerb were included into the list of reimbursed drugs as results of the national health insurance negotiations in July 2017.
  • Announced a strategic partnership with academia to co-develop health big-data system and upgrade the management of respiratory diseases in June 2017.
  • Aided the National Preventive Vaccination Services and Management Training Programme, helmed by the Chinese Preventive Medicine Association under the guidance of the National Health and Family Planning Commission, with the support of the China Centre for Disease Control and Prevention that officially kicked off in June 2017.
  • Viread, Arixtra, Requip and Mivacron were included in the “2017 National Reimbursement Drug List” in March 2017.

?

GSK – a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com.

?

GSK commitment to China

We are a science-led global healthcare company. We research, develop and manufacture a wide range of medicines, vaccines and consumer healthcare products. People are at the heart of what we do. We strive to bring high quality, high performing products to everyone who needs them. Creating innovative products and improving access to them is critical to our mission, allowing us to help build stronger, healthier communities. In China, and around the world, we are on a mission to help people do more, feel better, live longer. We are in China, with China, for China, and our commitment remains unwavering.

?

Media enquiries:

Susan Song????? susan.s.song@gsk.com ?????????? (GSK China)